Seikagaku: Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on Gel-One in Japan
Seikagaku: Notice of conclusion of a basic agreement on joint development and sales partnership for osteoarthritis treatment “Gel-One”
Seikagaku: Notice regarding organizational changes and changes in officers, etc.
Seikagaku: Receipt of an examination completion report notification relating to the US approval application for SI-6603 (generic name: chondriase)
Seikagaku: Notice regarding the commencement of phase III clinical trials of the osteoarthritis remedy “Gel-One” in Japan
Seikagaku: Notice regarding changes in officers, etc.
Seikagaku: Notice regarding approval of the endoscopic submucosal injection material “MuCoUP” in China and the conclusion of a sales agency agreement with Tozai Trading Co., Ltd.
Seikagaku: Notice regarding organizational changes and personnel changes
Seikagaku: Announcements of individual stocks related to personnel changes.
Seikagaku: Announcements of individual stocks regarding the scheduled submission date of securities reports.
Seikagaku: Announcements of individual stocks related to personnel changes.
Seikagaku: Independent Officer Notification Form
Seikagaku: Notice regarding acceptance of the SI-6603 approval application by the US FDA
Seikagaku: Notice regarding changes in officers
Seikagaku: Announcement of an academic conference presentation on SI-6603 by Ferring Pharmaceuticals
Biochemical Industry: Notice regarding organizational changes and personnel changes
Seikagaku: Notice regarding the postponement of the announcement of financial results for the 3rd quarter of the fiscal year ending March 31, 2024
Seikagaku: Notice of support for the Reiwa 6 Noto Peninsula Earthquake
Seikagaku: Notice regarding personnel changes
Seikagaku: Notice Concerning Pivotal Test Results for Anti-Adhesion Material SI-449